Letourneau Megan, Wells George, Walop Wikke, Duclos Philippe
Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada.
Drug Saf. 2008;31(5):389-98. doi: 10.2165/00002018-200831050-00003.
The WHO Programme for International Drug Monitoring (PIDM) was established in 1968 following the thalidomide disaster. The PIDM has had considerable success in analyzing drug-related adverse event reports, but more limited progress has been made in analyzing vaccine-related reports. In June 2005, the Global Advisory Committee on Vaccine Safety, acknowledging these limitations, called for a global consultation to address the need for improved monitoring and analysis of vaccine-related adverse event reports on an international level.
In preparation for this consultation and as part of a larger study designed to evaluate the PIDM, a survey of the National Pharmacovigilance Centres of all 76 countries participating in the PIDM at the time the survey was conducted.
Thirty-six countries (47%) responded. Of the 36 responding countries, 16 (44%) reported having a separate surveillance system for adverse events following immunizations (AEFIs) and 30 (83%) reported forwarding AEFI reports to the PIDM. Seven of the 36 countries (19%) indicated that one or more population subgroups are systematically excluded from their country's AEFI surveillance system. Five of the seven countries exclude reports concerning recipients of travellers' vaccines; three exclude recipients of vaccines administered by private physicians outside the national immunization programme and supply scheme; and five exclude reports from the military sector. Only half of the respondents knew of the Brighton Collaboration, a major international initiative aimed at the standardization of AEFI definitions.
The survey identified critical elements that should be addressed quickly to improve global vaccine safety monitoring. Communication between national adverse drug reaction and AEFI surveillance authorities, ability to pay for advancing technology in developing countries, and proper use of services and terminologies are issues of concern.
世界卫生组织国际药品监测规划(PIDM)于1968年在沙利度胺灾难后设立。PIDM在分析与药物相关的不良事件报告方面取得了相当大的成功,但在分析与疫苗相关的报告方面进展较为有限。2005年6月,全球疫苗安全咨询委员会认识到这些局限性,呼吁进行全球磋商,以满足在国际层面改进疫苗相关不良事件报告监测与分析的需求。
为此次磋商做准备,并作为旨在评估PIDM的一项更大规模研究的一部分,对调查开展时参与PIDM的所有76个国家的国家药物警戒中心进行了一项调查。
36个国家(47%)作出了回应。在这36个作出回应的国家中,16个(44%)报告称设有针对免疫接种后不良事件(AEFI)的单独监测系统,30个(83%)报告将AEFI报告转发给了PIDM。36个国家中有7个(19%)表示其国家的AEFI监测系统系统性地排除了一个或多个群体亚组。这7个国家中有5个排除了与旅行者疫苗接种者相关的报告;3个排除了国家免疫规划和供应计划之外由私人医生接种疫苗者的报告;5个排除了来自军事部门的报告。只有一半的受访者知晓布莱顿协作组织,这是一项旨在使AEFI定义标准化的重大国际倡议。
该调查确定了为改进全球疫苗安全监测应迅速解决的关键要素。国家药品不良反应和AEFI监测当局之间的沟通、发展中国家支付先进技术费用的能力以及服务和术语的正确使用都是令人关切的问题。